In any case, the company is currently ranked #3 (hold) by Zacks.įigure 2: Moderna and Pfizer/BioNTech: Cumulative incidence and effectiveness of coronavirus infections. In view of the increased costs and expenses associated with the development of candidate vaccines, the net loss exceeded $230,000. In the same quarter last year, the company reported sales of approximately $158 million, while earnings per share were lower than analysts’ expectations, at $0.59. In the forthcoming earnings announcement, the market estimates that Moderna’s reported sales will continue to increase to $6.2 billion, with earnings per share at $9.09, both representing an increase of nearly 41% from the previous quarter. These satisfactory results are mainly due to the sales of its coronavirus vaccine.įigure 1: Moderna’s quarterly reported sales and earnings per share.

Earnings per share (EPS) has remained positive throughout 2021, last reported at $6.46 ($0.31 in the same period last year), and earnings unexpectedly were 7.49%. Net income from the same period last year was, $1.17 billion to $28 billion. The company’s sales reached $4.4 billion, a significant improvement from the $67 million in the same period in 2020. In the last quarter, Moderna’s performance was in line with analyst expectations. It is a US-based pharmaceutical and biotechnology company that focuses on mRNA technology and development, including the development of drugs to treat various diseases and vaccines that have specifically helped curb the outbreak of new coronavirus infections. Moderna Company (#Moderna) plans to report its third-quarter earnings report tomorrow before the market open.

Nvda stock forecast tomorrow